<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Prostate biopsy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Prostate biopsy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Prostate biopsy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian M Benway, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wenliang Chen, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prostate biopsy is a minimally invasive procedure in which tissue samples are obtained from the prostate gland for the purpose of detecting the presence of cancer.
        </p>
        <p>
         Prostate biopsy techniques and periprocedural management will be reviewed here. Other aspects of prostate biopsy are discussed in other topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">
          "Screening for prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/97482.html" rel="external">
          "The role of magnetic resonance imaging in prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6922.html" rel="external">
          "Active surveillance for males with clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1261487055">
         <span class="h1">
          PROSTATE ANATOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prostate gland is a firm, walnut-shaped structure located at the base of the urinary bladder; the apex is caudal and the base cranial. The prostate is composed of both glandular and stromal (smooth muscle) tissue. Secretions from the prostate, vas deferens, and seminal vesicle empty into the prostatic urethra (ie, section of the urethra that traverses the prostate); each of these structures contributes to the composition of the semen  (
         <a class="graphic graphic_figure graphicRef54803" href="/z/d/graphic/54803.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The prostate gland is divided into three general zones  (
         <a class="graphic graphic_figure graphicRef57801" href="/z/d/graphic/57801.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral
         </strong>
         – Approximately 70 percent of the prostate gland is contained within the peripheral zone, and the majority of prostate cancers originate within this zone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central
         </strong>
         – The central zone comprises 25 percent of the volume of the normal prostate with an increased proportion in men with benign prostatic hyperplasia. The stroma of the prostate gland is the densest in this zone. Approximately 5 percent of prostate cancers originate within the central zone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transition
         </strong>
         – The transition zone comprises 5 percent of the normal volume of the prostate and is the site of benign prostatic hyperplasia. Approximately 10 percent of cancers originate within the transition zone.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prostate biopsy is usually performed to diagnose or exclude prostate cancer.
        </p>
        <p>
         Indications for the
         <strong>
          initial
         </strong>
         prostate biopsy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal serum prostate-specific antigen (PSA) level. However, what constitutes an abnormal PSA level, and which patients with an abnormal PSA level should be biopsied, are complicated and evolving questions, which are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer", section on 'PSA testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer", section on 'Decision to biopsy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal digital rectal examination (DRE). Abnormal findings on DRE include the presence of nodules, induration, or asymmetry. (See
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer", section on 'Digital rectal examination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Indications for
         <strong>
          repeat
         </strong>
         prostate biopsies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inadequate initial biopsy, atypical findings on initial biopsy, or continued high clinical suspicion for prostate cancer after initial negative biopsy based upon rising PSA levels or a variety of other PSA-based parameters (eg, PSA velocity, PSA density, or abnormalities in "reflex" blood or urine tests). (See
         <a class="local">
          'Repeat biopsy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active surveillance of low-risk, clinically localized prostate cancer. Active surveillance for men with clinically localized prostate cancer at low risk for progression utilizes observation rather than immediate therapy, with curative-intent treatment may be deferred indefinitely (in most cases) or until there is evidence of disease progression [
         <a href="#rid1">
          1
         </a>
         ]. Repeat prostate biopsy is generally recommended within the first year or two, then every two to five years to rule out high-grade disease missed on the original biopsy. (See
         <a class="medical medical_review" href="/z/d/html/6922.html" rel="external">
          "Active surveillance for males with clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The approach and method of prostate biopsy should be tailored to the indication. (See
         <a class="local">
          'Choice of biopsy method by indication'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2583783520">
         <span class="h1">
          CHOICE OF BIOPSY METHOD BY INDICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prostate biopsy can be systematic, targeted, or both, the choice of which depends on demonstration of suspicious findings on prebiopsy magnetic resonance imaging (MRI). The requirement for prebiopsy MRI further depends on whether the patient has had prior prostate biopsy  (
         <a class="graphic graphic_algorithm graphicRef142833" href="/z/d/graphic/142833.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H560058656">
         <span class="h2">
          Initial biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients undergoing prostate biopsy for the first time, an MRI may be performed, and if there is a suspicious lesion(s), a targeted biopsy should be performed with a concurrent systematic biopsy. There are limited data to suggest that this approach may increase the detection rate of clinically significant prostate cancer. (See
         <a class="local">
          'Targeted biopsy'
         </a>
         below.)
        </p>
        <p>
         However, due to issues related to the quality of imaging and interpretation, targeting strategies, as well as cost and availability [
         <a href="#rid2">
          2,3
         </a>
         ], there are insufficient data to recommend routine MRI prior to every initial biopsy [
         <a href="#rid2">
          2
         </a>
         ]. Systematic biopsy alone remains a reasonable approach to the initial biopsy [
         <a href="#rid4">
          4,5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97482.html" rel="external">
          "The role of magnetic resonance imaging in prostate cancer", section on 'Initial presentation with no prior biopsy'
         </a>
         .)
        </p>
        <p>
         Patients should proceed with a systematic biopsy if there are no suspicious findings on MRI.
        </p>
        <p class="headingAnchor" id="H2330623722">
         <span class="h2">
          Patients with negative systematic biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A negative systematic biopsy in the face of clinically determined need or indication for a prostate biopsy is the most validated and accepted indication for prostate MRI and MRI-targeted biopsy. There is increasing evidence that MRI-targeted biopsy can increase clinically significant cancer detection over standard systematic biopsy alone [
         <a href="#rid6">
          6,7
         </a>
         ], and this advantage is more pronounced when MRI-targeted biopsy is performed in men with a prior negative biopsy than biopsy-naïve men [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Targeted biopsy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/97482.html" rel="external">
          "The role of magnetic resonance imaging in prostate cancer"
         </a>
         .)
        </p>
        <p>
         At facilities where prostate MRI and MRI-targeted biopsy are available, they should be performed for patients with one or more prior negative systematic biopsies. MRI-targeted biopsy should be performed with concurrent systematic sampling, or else clinically significant cancer can be missed by targeted biopsies alone [
         <a href="#rid9">
          9-11
         </a>
         ]. (See
         <a class="local">
          'Targeted biopsy'
         </a>
         below.)
        </p>
        <p>
         If there are no suspicious findings on the MRI, the patient should proceed with a repeat systematic biopsy. A more elaborate scheme of sampling such as saturation biopsy or template-guided biopsy may be considered. (See
         <a class="local">
          'Repeat systematic biopsy'
         </a>
         below and
         <a class="local">
          'Template-guided transperineal biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H927624975">
         <span class="h2">
          Active surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeat prostate biopsy for men under active surveillance for low-risk clinically localized prostate cancer is generally recommended to rule out high-grade disease missed on the original biopsy. (See
         <a class="medical medical_review" href="/z/d/html/6922.html" rel="external">
          "Active surveillance for males with clinically localized prostate cancer"
         </a>
         .)
        </p>
        <p>
         The current American Urologic Association recommendation is to obtain prostate MRI if the initial (diagnostic) prostate biopsy was performed without MRI guidance. If the MRI demonstrates suspicious findings (Prostate Imaging Reporting and Data System [PI-RADS] 4 or 5), a repeat (confirmatory) targeted biopsy should be performed as soon as possible. If the MRI is assessed as PI-RADS 1, 2, or 3, then repeat systematic biopsy may be performed within approximately 12 months. Thereafter, serial surveillance biopsies are recommended every one to four years depending on patient condition [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          PREPARATION
         </span>
        </p>
        <p class="headingAnchor" id="H1918904512">
         <span class="h2">
          Test for and treat urinary tract infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of bacteriuria or an indwelling catheter at the time of biopsy increases the risk of postbiopsy urinary tract infection and other infectious complications [
         <a href="#rid13">
          13-16
         </a>
         ]. Thus, a urinalysis should be performed prior to biopsy. If the urinary findings are suspicious for bacteriuria, the biopsy is postponed, urine cultures are obtained, and a short course (five to seven days) of culture-appropriate antibiotics is administered. (See
         <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">
          "Antimicrobial prophylaxis for prevention of surgical site infection in adults", section on 'Genitourinary surgery'
         </a>
         and
         <a class="local">
          'Infection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Prophylactic antibiotics
         </span>
        </p>
        <p class="headingAnchor" id="H2745599553">
         <span class="h3">
          Transrectal biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend antibiotic prophylaxis prior to transrectal prostate biopsy [
         <a href="#rid17">
          17,18
         </a>
         ]. We typically use a single dose of an oral fluoroquinolone one hour prior to prostate biopsy  (
         <a class="graphic graphic_table graphicRef129971" href="/z/d/graphic/129971.html" rel="external">
          table 1
         </a>
         ).
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          Gentamicin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         is the most commonly used intramuscular alternative to fluoroquinolone; another intravenous alternative is
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         .
        </p>
        <p>
         A 2011 Cochrane meta-analysis of nine trials found that antibiotic administration prior to prostate biopsy reduces the risk of bacteriuria (risk ratio [RR] 0.25, 95% CI 0.15-0.42), bacteremia (RR 0.67, 95% CI 0.49-0.92), fever (RR 0.39, 95% CI 0.23-0.64), urinary tract infection (RR 0.37, 95% CI 0.22-0.62), and need for hospitalization (RR 0.13, 95% CI 0.03-0.55) [
         <a href="#rid19">
          19
         </a>
         ]. Severe infectious complications, such as sepsis, Fournier gangrene, and urinary tract infection requiring hospital admission, have been reported in patients who did not receive prophylactic antibiotics [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Fluoroquinolones are the most widely used antibiotic for prophylaxis due to their broad spectrum of activity, easy oral administration, good penetration to prostate gland tissue, and long-lasting bactericidal activity. However, resistance to fluoroquinolones is rising. Thus, clinicians should review their local antibiograms and, if the fluoroquinolone-resistance rate for
         <em>
          Escherichia coli
         </em>
         is &gt;20 percent, choose another class of antibiotics [
         <a href="#rid17">
          17
         </a>
         ]. Alternatively, for patients at high risk of harboring resistant organisms (eg, diabetes, immunosuppression, recurrent urinary tract infections, antibiotics within six months, health care workers, or recent international travel), rectal swab cultures may be taken to direct antibiotic selection [
         <a href="#rid21">
          21-25
         </a>
         ]. In a trial, rectal cultured-based prophylactic antibiotics reduced the seven-day infection rate from 4.3 to 2.5 percent compared with empirical antibiotics [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Practices vary worldwide. A meta-analysis of 59 trials comparing seven different prophylactic antibiotic regimens found that in countries where fluoroquinolones are allowed as antibiotic prophylaxis, a minimum of a full one-day administration as well as targeted therapy in case of fluoroquinolone resistance is recommended [
         <a href="#rid27">
          27
         </a>
         ]. In countries with a ban on fluoroquinolones,
         <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">
          fosfomycin
         </a>
         is a good alternative, as is augmented prophylaxis, although no established standard combination exists to date.
        </p>
        <p class="headingAnchor" id="H3082852002">
         <span class="h3">
          Transperineal biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether antibiotic prophylaxis is required for transperineal prostate biopsy is controversial because transperineal biopsy is associated with a lower risk of infection compared with transrectal biopsy. Our contributors do not find it necessary except for patients with risk factors (eg, immunocompromised).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2022 meta-analysis of 106 cohort studies, antibiotic prophylaxis was not associated with a lower incidence of septic complications (0.05 versus 0.08 percent) or overall infectious complication (1.22 versus 1.35 percent) compared with nonantibiotic prophylaxis [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of 555 patients, no patient developed sepsis or urinary tract infection requiring hospitalization after transperineal biopsy; only one patient who received antibiotic prophylaxis and three patients who did not receive antibiotic prophylaxis developed a urinary tract infection that did not require hospitalization [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Rectal cleansing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rectal cleansing with enemas, suppositories, or iodine lavage is not necessary as long as appropriate antibiotic prophylaxis is provided [
         <a href="#rid30">
          30
         </a>
         ]. The potential benefit of enema administration or povidone-iodine lavage prior to prostate biopsy is based upon the supposition that these measures will reduce infectious complications due to transmission of bacteria from the rectal vault [
         <a href="#rid31">
          31
         </a>
         ]. In patients who have received antibiotic prophylaxis, a clinically significant benefit from rectal cleansing has not been found [
         <a href="#rid19">
          19,32
         </a>
         ]. In addition to lack of benefit, improper or incomplete enema technique may hinder visualization and increase patient discomfort [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2861997634">
         <span class="h2">
          Equipment sterilization
         </span>
         <span class="headingEndMark">
          —
         </span>
         For procedures in which ultrasonography is performed, sterile ultrasound transmission gel should be used. Outbreaks of infection due to resistant organisms have been traced to contaminated gel from multiple-use tubes [
         <a href="#rid34">
          34
         </a>
         ]. Some authors have recommended formalin disinfection of the biopsy needle after each core is taken to minimize postbiopsy infection [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Antiplatelet therapy/anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients undergoing prostate biopsy are taking anticoagulants or antiplatelet agents for cardiovascular diseases. The decision to withhold or continue these agents requires clinical judgment weighing the risk of a significant cardiovascular event against the risk of bleeding [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         The practices of urologists vary. Some continue low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         but discontinue
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         ,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , or direct oral anticoagulants, and others continue all anticoagulants if clinically indicated (ie, discontinuation could increase the risk of cardiovascular adverse events), while others favor discontinuing all anticoagulants if clinically safe.
        </p>
        <p>
         Data suggest that the continued use of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         therapy at the time of prostate biopsy may not be associated with an increase in risk for local bleeding complications [
         <a href="#rid37">
          37-40
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients on
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , two trials did not identify an increased risk of clinically significant hemorrhage in patients who remained on aspirin in the periprocedural period [
         <a href="#rid38">
          38,39
         </a>
         ]. In the larger of these trials, 200 men on low-dose aspirin were randomly assigned to continue low-dose aspirin, discontinue low-dose aspirin, or replace low-dose aspirin with low-molecular-weight heparin (LMWH); systematic 10-core prostate biopsy was performed [
         <a href="#rid38">
          38
         </a>
         ]. No severe bleeding complications occurred in any of the patients, although the duration of minor bleeding was significantly longer in the patients on low-dose aspirin or LMWH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         therapy, a prospective observational study evaluating the risk of bleeding in patients undergoing sextant biopsy identified no significant differences in the incidence or severity of rectal bleeding, hematuria, or hematospermia in the patients who remained on warfarin compared with those who were not anticoagulated [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         There are no data on the risk of bleeding with other antiplatelet medications, including
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , or with direct oral anticoagulants. In the absence of data, these agents are typically withheld [
         <a href="#rid41">
          41
         </a>
         ]. The general principles of perioperative antiplatelet/anticoagulation management are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">
          "Perioperative medication management", section on 'Medications affecting hemostasis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H976116163">
         <span class="h2">
          Sedation/analgesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients are understandably anxious and may benefit from administration of an anxiolytic prior to undergoing prostate biopsy [
         <a href="#rid42">
          42
         </a>
         ]. Multiple randomized trials have found that local anesthetic administration significantly reduces patient discomfort during prostate biopsy, especially in younger patients [
         <a href="#rid43">
          43-50
         </a>
         ]. In addition, the administration of local analgesia does not appear to increase the rate of complications following prostate biopsy [
         <a href="#rid48">
          48,51
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most urologist perform a periprostatic nerve block with plain
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         (2.5 mL of 1% or 2%) injected under ultrasound guidance at each junction between the seminal vesicle and the prostate [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some investigators have found that the addition of intraprostatic
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         administration may provide better analgesia than periprostatic blockade alone, despite the risk of increased pain at the time of administration [
         <a href="#rid54">
          54-57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          Nitroglycerin
         </a>
         (glyceryl trinitrate) ointment may be useful in some patients due to its ability to relax the anal sphincter [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         For patients who are particularly anxious and those undergoing a saturation biopsy, prostate biopsy can also be performed with regional anesthetic techniques (eg, saddle block, pudendal block) [
         <a href="#rid59">
          59,60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5404.html" rel="external">
          "Pudendal and paracervical block"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4278038338">
         <span class="h1">
          SYSTEMATIC VERSUS TARGETED BIOPSY
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is increasing evidence that MRI-targeted biopsy can increase clinically significant cancer detection over transrectal ultrasound (TRUS)-based systematic biopsy alone, and this advantage is more pronounced when MRI-targeted biopsy is performed in men with a prior negative biopsy than biopsy-naïve men.
        </p>
        <p class="headingAnchor" id="H1094980417">
         <span class="h2">
          Systematic biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRUS-guided prostate biopsy is based on systematic prostate sampling and augmented by additional sampling of any abnormal areas (eg, hypoechoic) found on ultrasound or rectal examination [
         <a href="#rid61">
          61
         </a>
         ]. Multiple sampling schemes have been developed in an effort to improve the accuracy in the detection of cancer.
        </p>
        <p class="headingAnchor" id="H3395913364">
         <span class="h3">
          Initial systematic biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For an initial TRUS-guided biopsy, society guidelines from North America and Europe generally recommend obtaining 10 to 12 cores systematically by incorporating apical and far-lateral regions of the prostate [
         <a href="#rid62">
          62
         </a>
         ]. Compared with a 10- or 12-core biopsy, a 6-core biopsy could miss a third of the cancer, whereas collecting more than 12 cores or sampling the transition zone offers no additional benefit for an initial biopsy. A smaller number of cores may be adequate for patients with low prostate volumes [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          10- to 12-core
         </strong>
         – Extended-core biopsy is performed by obtaining five to seven evenly distributed specimens from each side, sampling more extensively from the lateral aspects of the prostate [
         <a href="#rid64">
          64-67
         </a>
         ]. In selecting locations for sampling, the biopsy template should ensure adequate sampling of the apex or anterior apex, the far-lateral region (including the base, mid-gland, and apex), and the traditional sextant sites. Additional sampling from the transition zone does not improve yield [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          6-core
         </strong>
         – In the early era of TRUS-guided biopsy, a 6-core or sextant biopsy technique was commonly employed, taking one sample each from the apex, base, and mid-prostate on each side [
         <a href="#rid68">
          68
         </a>
         ]. A systematic review of 87 studies found that schemes with 12 core samples that took additional laterally directed cores detected 31 percent more cancers (95% CI 25-37) compared with a 6-core approach [
         <a href="#rid69">
          69
         </a>
         ]. Compared with 6-core biopsy, extended-core biopsy is not associated with an increased risk of infection, abdominal or rectal pain, or voiding difficulties. However, rectal bleeding and hematospermia may be more frequent [
         <a href="#rid69">
          69,70
         </a>
         ]. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          18-core
         </strong>
         – Another method extends initial biopsy to include 18 cores. This approach may be more effective in detecting premalignant pathology, but the overall success in diagnosing true cancer appears to be equivalent to a 12-core biopsy, except for those patients with prostate volume exceeding 55 cm
         <sup>
          3
         </sup>
         [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Prostate volume should also be taken into account [
         <a href="#rid63">
          63,72
         </a>
         ]. In a study of 500 men, for example, an 8-core prostate biopsy was sufficient for the detection of cancer in men whose prostate volume was less than 35 cm
         <sup>
          3
         </sup>
         [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Age may also play an important role in guiding the number of core samples obtained. The Vienna nomogram, developed from a large European cohort of men with a serum prostate-specific antigen between 2 to 10 ng/mL, suggested that at a given prostate volume, fewer cores are needed as age increases [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H34008980">
         <span class="h3">
          Repeat systematic biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Saturation biopsy is a form of TRUS-guided biopsy that involves extensive sampling of the prostate, obtaining up to 24 core samples. Compared with standard extended-core TRUS biopsy, saturation biopsy takes a greater number of cores in a better symmetric array throughout the entire prostate gland. Saturation techniques do not provide increased cancer detection when used for first-time biopsy but may provide increased sensitivity when repeat biopsies are performed and should be considered after one or more negative TRUS biopsies [
         <a href="#rid74">
          74-77
         </a>
         ], especially in areas where MRI-targeted biopsy is not available. Saturation biopsy detects prostate cancer in 22 to 33 percent of patients undergoing repeat biopsy [
         <a href="#rid78">
          78,79
         </a>
         ].
        </p>
        <p>
         Saturation biopsy is typically performed in the outpatient setting under regional or general anesthesia due to concerns for pain control, and because it is thought to be associated with an increased incidence of morbidity (eg, severe hematuria) requiring hospital admission [
         <a href="#rid78">
          78,79
         </a>
         ]. However, a systematic review that identified eight studies comparing saturation with extended biopsy found no significant differences in infection, hematuria, or bleeding between the groups [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2996750022">
         <span class="h3">
          Limited value of FNA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fine needle aspiration (FNA) smears lack architectural detail and are
         <strong>
          not
         </strong>
         considered sufficiently accurate to definitively diagnose prostate cancer [
         <a href="#rid81">
          81
         </a>
         ]. As a result, some premalignant histology cannot be adequately distinguished from prostate cancer, even by an experienced pathologist. FNA of the prostate gland is particularly unreliable in men who have undergone hormonal or radiation therapy. However, FNA may have a role in confirming advanced prostate cancer or metastatic disease in men with a prior history of localized cancer.
        </p>
        <p class="headingAnchor" id="H4192626245">
         <span class="h2">
          Targeted biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI-defined lesions can be targeted for biopsy in several ways [
         <a href="#rid64">
          64,82-93
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cognitive targeting refers to a method in which the clinician identifies the lesion on MRI and uses the anatomic information to select the area during TRUS-guided prostate biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Targeting within the magnet (ie, "in-bore" targeting) is a technique in which MRI is used to directly guide prostate biopsy in real-time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of registration or fusion software (eg, Koelis Urostation, UroNav, Artemis) allows a lesion targeted on MRI to be identified again during a later TRUS-guided biopsy procedure, either with or without a tracking device [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The superiority of any specific approach has not been established. However, among these three options, the most useful for urologists, who perform the majority of prostate biopsies, may be the MRI/TRUS fusion-guided technique [
         <a href="#rid64">
          64,91,95-98
         </a>
         ]. At some institutions, including those of most of the authors and editors of this topic, all men who have access to it undergo prostate MRI prior to planned TRUS biopsy. When performing an MRI-targeted biopsy with fusion software, the urologist needs to take 4- to 6-core biopsies around the target to identify the most aggressive portion of the tumor [
         <a href="#rid99">
          99
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97482.html" rel="external">
          "The role of magnetic resonance imaging in prostate cancer", section on 'Multiparametric imaging'
         </a>
         .)
        </p>
        <p>
         The available evidence suggests that incorporation of prebiopsy MRI in the diagnostic pathway for a clinically suspected prostate cancer improves the diagnosis of clinically significant disease, reduces adverse effects from biopsy, and can potentially prevent unnecessary biopsies in some individuals.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the PROMIS trial, 576 biopsy-naïve men underwent prostate MRI followed by both TRUS-guided systematic biopsy and template biopsy. Compared with TRUS biopsy, MRI was more sensitive (93 versus 48 percent) but less specific (41 versus 96 percent) in detecting clinically significant cancer [
         <a href="#rid100">
          100
         </a>
         ]. Using MRI to triage men might have negated biopsy in about a quarter of patients and diagnosed 5 percent fewer clinically insignificant cancers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the PRECISION trial, 500 biopsy-naïve men were randomly assigned to undergo MRI with (72 percent) or without (28 percent) targeted biopsy (depending on whether MRI revealed a target lesion) or standard TRUS biopsy [
         <a href="#rid101">
          101
         </a>
         ]. The MRI "pathway" detected more clinically significant cancers (38 versus 26 percent; adjusted difference 12 percent, 95% CI 4-20) and fewer clinically insignificant cancers (9 versus 22 percent; adjusted difference -13 percent, 95% CI -19 to -7) than standard TRUS biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another trial, 212 biopsy-naïve men were randomly assigned to either undergo MRI followed by either MRI-targeted biopsy (76 percent) or TRUS biopsy (24 percent without an MRI-visible lesion) or undergo standard TRUS biopsy [
         <a href="#rid102">
          102
         </a>
         ]. This slightly different MRI "pathway" also detected more cancers overall (51 versus 30 percent) and more clinically significant cancers (44 versus 18 percent) than standard TRUS biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another Canadian trial, 453 biopsy-naïve men underwent either TRUS biopsy or multiparametric MRI followed by MRI-targeted biopsy of any PI-RAD ≥3 lesions. MRI-targeted biopsy identified more clinically significant prostate cancers than TRUS biopsy (35 versus 30 percent) while sparing biopsy in 37 percent of men who had a negative MRI. MRI-targeted biopsy also resulted in fewer complications and identified fewer clinically insignificant cancers compared with TRUS biopsy [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2019 Cochrane review compared the test accuracy of prostate MRI, MRI-targeted biopsy, MRI pathway (MRI with or without MRI-targeted biopsy), and systematic TRUS biopsy in prostate cancer diagnosis in both men with and without a prior biopsy, using template-guided biopsy as the reference standard [
         <a href="#rid7">
          7
         </a>
         ]. It concluded that, within the limitation of the studies analyzed, the MRI pathway has the most favorable diagnostic accuracy in clinically significant prostate cancer detection (pooled sensitivity 0.72 [95% CI 0.60-0.82]; pooled specificity 0.96 [95% CI 0.94-0.98]) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Whether MRI-targeted biopsy should be performed with or without concurrent systematic sampling is controversial [
         <a href="#rid6">
          6
         </a>
         ]. Based on the following data, we suggest concurrent targeted and systematic sampling:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) trial, 248 biopsy-naïve men with MRI-visible lesions underwent systematic, cognitive fusion, and software fusion biopsies [
         <a href="#rid11">
          11
         </a>
         ]. Targeted biopsies had higher cancer detection rates per core than systematic biopsy (38 percent software versus 33 percent cognitive versus 15.7 percent systematic), but fewer cores are taken with targeted biopsy (6 versus 12); thus, the overall cancer detection rate was similar at 60 percent for systematic and targeted biopsy. The overall cancer detection rate was greatest (70 percent) when systematic and targeted results were combined, as discordance of tumor locations suggested that the different biopsy methods detect different tumors. Overall, 21 percent had cancer detected by systematic biopsy that was missed by an MRI-targeted biopsy, while 10 percent had cancer detected by targeted biopsy that was missed by systematic biopsy. A control group of 52 men without MRI-visible lesion underwent systematic biopsy, which detected cancer in 15 percent. Thus, a negative MRI result should not obviate the need for prostate biopsy when otherwise clinically indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study, 2103 men with MRI-visible lesions underwent both MRI-targeted and systemic biopsy (79 percent had prior biopsy) [
         <a href="#rid104">
          104
         </a>
         ]. Combined biopsy detected more cancers than either method alone (62.4 percent combined; 51.5 percent with MRI; 52.5 percent with systematic biopsy) and was associated with the fewest clinically significant upgrades (defined in this study as grade group 3 or higher  (
         <a class="graphic graphic_table graphicRef107132" href="/z/d/graphic/107132.html" rel="external">
          table 2
         </a>
         )) in those who underwent prostatectomy (3.5 percent combined; 8.7 percent with MRI; 16.8 percent with systematic biopsy). The corresponding rates for upgrades to grade group 2 or higher disease were 6.7 percent for combined biopsy versus 18.3 and 30.2 percent for targeted and systematic biopsies, respectively. Downgrading to clinically insignificant cancer (grade group 1) on histopathologic analysis of the prostatectomy specimen was uncommon overall and not significantly different among the three groups (3.5 percent of those undergoing combined biopsy versus 2.2 and 2.5 percent for systematic and MRI-targeted biopsy, respectively).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1076791812">
         <span class="h1">
          IMAGE GUIDANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prostate biopsy was historically performed with manual guidance, but transrectal ultrasound (TRUS)-guided or MRI-guided biopsies are most commonly performed nowadays.
        </p>
        <p class="headingAnchor" id="H3679673281">
         <span class="h2">
          Ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRUS-guided biopsy is the most common approach for prostate biopsy. TRUS biopsy is most often performed in the urologist's office with local anesthesia and no sedation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Two-dimensional TRUS
         </strong>
         is typically used for measuring prostate volume. Prostate height and width are measured in a longitudinal plane, and then the probe orientation is switched on the machine to measure length and width in the transverse plane. The software contains an algorithm that reliably computes prostate volume based upon these measurements. Prostate volume and prostate-specific antigen (PSA) density (PSA level/prostate volume) are easily calculated and may aid in determining the sample size on prostate biopsy. Patients with larger prostates (eg, those with benign prostatic hyperplasia) may have a PSA level higher than normal due to increased prostate volume [
         <a href="#rid105">
          105
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7568.html" rel="external">
          "Measurement of prostate-specific antigen", section on 'PSA density'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The prostate should be visualized in both the sagittal and longitudinal planes, and the overall echotexture of the prostate and seminal vesicles are assessed and correlated with the findings of digital rectal examination and potential underlying histology [
         <a href="#rid106">
          106
         </a>
         ]. The normal prostate has a uniform echotexture  (
         <a class="graphic graphic_diagnosticimage graphicRef76064" href="/z/d/graphic/76064.html" rel="external">
          image 1
         </a>
         ). Hypoechoic lesions and those that correlate with an abnormality on digital rectal examination have a higher likelihood of harboring cancer; however, up to one-third of (and possibly more) prostate cancers are isoechoic [
         <a href="#rid107">
          107,108
         </a>
         ]. Hyperechoic areas represent areas of prostatic calcification (ie, stones).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Three-dimensional TRUS
         </strong>
         can provide additional information about the location and extent of prostate cancer (eg, seminal vesicle invasion, extension through the prostatic capsule); however, three-dimensional imaging devices are not widely available in the office setting and their advantage over standard TRUS biopsy is debated [
         <a href="#rid109">
          109-112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enhanced ultrasound techniques
         </strong>
         have been introduced to manage some of the limitations of traditional grayscale ultrasound-guided biopsy techniques, primarily the relatively low sensitivity for prostate cancer [
         <a href="#rid106">
          106,113-117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One technique uses Doppler imaging to identify areas of increased vascularity, which can be further augmented using contrast agents [
         <a href="#rid118">
          118-125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Another technique, elastosonography, evaluates differences in tissue response to manual compression [
         <a href="#rid126">
          126-130
         </a>
         ]. Elastosonography has shown promise for enhancing the resolving power of ultrasound, and, although results are conflicting, several reports indicate that elastosonography is capable of identifying foci of cancer, with improved sensitivity for higher-grade cancers. Potential limitations of this technology include the need for specialized ultrasound probes and the reliance upon operator skill to define areas of differential elasticity [
         <a href="#rid131">
          131-134
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Another emerging technique, microultrasound-guided biopsy [
         <a href="#rid135">
          135-138
         </a>
         ], allows use of Prostate Risk Identification Using Microultrasound (PRI-MUS) protocol to characterize and target lesions similar to the Prostate Imaging Reporting and Data System (PI-RADS) protocol for multiparametric MRI [
         <a href="#rid139">
          139
         </a>
         ]. Microultrasound seems to be equivalent to MRI for imaging prostate cancer [
         <a href="#rid138">
          138
         </a>
         ]. A head-to-head trial of microultrasound- versus MRI-guided prostate biopsy is ongoing [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1830941032">
         <span class="h2">
          MRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI provides superior resolution of prostate anatomy and potential targets for biopsy (especially anterior tumors) compared with other imaging modalities [
         <a href="#rid141">
          141
         </a>
         ]. Major technical improvements in prostate multiparametric MRI with the standard approach to interpretation using the Prostate Imaging Reporting and Data System (PI-RADS) have rapidly expanded the role of MRI in prostate cancer management in many clinical contexts, both prior to and following diagnosis, which is discussed in detail elsewhere [
         <a href="#rid93">
          93,142-145
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97482.html" rel="external">
          "The role of magnetic resonance imaging in prostate cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with a PI-RADS category 3 to 5 lesion warrant repeat biopsy with image-guided, targeted biopsy. The MRI/TRUS fusion or in-bore targeting technique is more reliable, especially for small lesions or lesions in difficult locations (eg, anterior or apical prostate) [
         <a href="#rid146">
          146
         </a>
         ]. However, they are expensive. Cognitive targeting of other more accessible lesions is acceptable in skilled hands. At least two core samples should be obtained from each MRI target [
         <a href="#rid6">
          6
         </a>
         ]. In the Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) trial, the cancer detection rate was higher for PI-RADS 4 (64 percent) and 5 (80 percent) lesions than for PI-RADS 3 lesions (23 percent) [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Targeted biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with a PI-RADS category 1 or 2 lesion may or may not need a repeat biopsy, depending on clinical suspicion and other ancillary markers (eg, PSA velocity, PSA density, or biomarkers). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scanning may be helpful. This is controversial and further discussed in another topic. (See
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer", section on 'Decision to biopsy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2703579922">
         <span class="h1">
          ANATOMIC APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two main anatomic approaches to prostate biopsy are transrectal (TRUS) and transperineal, the use of which varies widely by country and within regions of specific countries [
         <a href="#rid147">
          147
         </a>
         ]. The reported cancer detection rates associated with transrectal versus transperineal biopsy route are not significantly different [
         <a href="#rid148">
          148-151
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4135189442">
         <span class="h2">
          Transrectal biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRUS biopsy is typically performed by urologists in the office setting.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient is placed in a lateral decubitus position, with the knees and hips flexed 90 degrees [
         <a href="#rid152">
          152
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With appropriate lubrication, the ultrasound probe  (
         <a class="graphic graphic_figure graphicRef75517" href="/z/d/graphic/75517.html" rel="external">
          figure 3
         </a>
         ) is gently inserted into the rectum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A preprocedure TRUS and digital rectal examination are performed to confirm previous findings. The prostate is imaged, and prostate volume is determined. (See
         <a class="local">
          'Ultrasound'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An 18-gauge spring-loaded core biopsy needle (eg, Tru-Cut) is advanced into the rectum adjacent to the ultrasound probe and guided into the prostate to obtain core samples, one at a time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The specimen is removed from the biopsy gun and examined. The core should measure 0.1 cm in diameter and 1.0 to 1.5 cm in length [
         <a href="#rid153">
          153
         </a>
         ]. Inadequate cores require resampling from the same region. The specimens are labeled according to location before being sent for pathologic analysis. Society guidelines recommend putting no more than two cores in each specimen container to avoid tissue fragmentation or tangling [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H97456144">
         <span class="h2">
          Transperineal biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transperineal procedures are most often performed in an outpatient hospital setting by a urologist alone or in conjunction with a radiologist, although newer MRI fusion biopsies can be performed by urologists in the office setting.
        </p>
        <p>
         Transperineal biopsy can be performed with conventional ultrasound, microultrasound, computed tomography, or MRI guidance, and the overall diagnostic accuracy appears to be equivalent to that of transrectal TRUS [
         <a href="#rid154">
          154-157
         </a>
         ].
        </p>
        <p>
         Transperineal biopsy has a lower risk of infectious complications and thus could potentially avoid the need for broad-spectrum antibiotic prophylaxis [
         <a href="#rid158">
          158,159
         </a>
         ], although whether routine antibiotic prophylaxis is required before transperineal prostate biopsy remains controversial [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="local">
          'Transperineal biopsy'
         </a>
         above.)
        </p>
        <p>
         However, the overall complication rates of transperineal biopsy were found to be similar to [
         <a href="#rid160">
          160
         </a>
         ] or higher than [
         <a href="#rid161">
          161,162
         </a>
         ] those of TRUS in older studies due to unique complications such as perineal hematoma. The risk of hematuria and hematospermia is similar between transperineal and transrectal biopsy [
         <a href="#rid163">
          163
         </a>
         ]. Transperineal biopsy is also typically more painful and requires general anesthesia to carry out in an operating room [
         <a href="#rid164">
          164
         </a>
         ], although in-office transperineal biopsy under local anesthesia has been proposed [
         <a href="#rid165">
          165,166
         </a>
         ]. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3120934649">
         <span class="h3">
          Template-guided transperineal biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A template-guided transperineal approach combines TRUS with transperineal biopsy guided by a brachytherapy template [
         <a href="#rid167">
          167-169
         </a>
         ]. The template is a tool that maximizes symmetric biopsy throughout the entire prostate gland. This enhanced localization augments the biopsy technique and may prove especially beneficial for repeat biopsy when premalignant pathology is found on initial biopsy. (See
         <a class="local">
          'Repeat biopsy'
         </a>
         below.)
        </p>
        <p>
         Core samples are obtained at 5 mm intervals throughout the prostate. Template-guided transperineal biopsy provides value to rule out prostate cancer, prevent overtreatment of those that can remain on active surveillance, evaluate focal therapy candidacy, and identify those needing whole-gland management [
         <a href="#rid109">
          109,110
         </a>
         ]. In one retrospective series of 117 men with prior negative biopsies, cancer and clinically significant cancer was detected in 64 and 50 percent, respectively; for 86 men on active surveillance, 42 percent had Gleason upgrading [
         <a href="#rid170">
          170
         </a>
         ]. In that study, template-guided transperineal biopsy changed management for 69 percent of patients, with 44 percent proceeding to whole-gland therapy and 24 percent electing focal therapy. Complication rate was 17 percent, with the majority of complications being minor.
        </p>
        <p class="headingAnchor" id="H2313125714">
         <span class="h3">
          In-office transperineal biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A new system that uses a trocar to minimize the number of skin punctures allows transperineal template prostate biopsy to be performed in office (or at an outpatient facility) with local anesthesia. It is performed under TRUS guidance. Initial results showed acceptable cancer detection rate and no infectious complications [
         <a href="#rid171">
          171,172
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3599658211">
         <span class="h2">
          Transurethral resection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients in whom suspicion for prostate cancer remains high in spite of aggressive negative sampling, transurethral resection of the prostate (TURP) can be performed [
         <a href="#rid173">
          173,174
         </a>
         ]. In a retrospective review, TURP detected cancer in 35 of 375 patients (9.3 percent) with one prior negative biopsy and in 6 of 35 patients with two prior negative biopsies [
         <a href="#rid173">
          173
         </a>
         ]. However, the evolution of MRI technology and template biopsy techniques have largely eliminated the need for TURP as a prostate biopsy technique. The transurethral route is diagnosing prostate cancer is now rarely used, perhaps only when the rectum is absent.
        </p>
        <p class="headingAnchor" id="H1248003557">
         <span class="h1">
          POSTBIOPSY FOLLOW-UP
         </span>
        </p>
        <p class="headingAnchor" id="H2443649038">
         <span class="h2">
          Patient instructions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postbiopsy pain is not common and generally responds to
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         . Nonsteroidal anti-inflammatory drugs are not commonly used because of the concern for bleeding.
        </p>
        <p>
         Patients may resume their normal activities, including sexual intercourse, following the procedure. Routine use of stool softeners after uncomplicated TRUS-guided biopsy is not necessary, although patients who develop prostatitis or urinary tract obstruction may benefit from their use. (See
         <a class="local">
          'Infection'
         </a>
         below and
         <a class="local">
          'Urinary obstruction'
         </a>
         below.)
        </p>
        <p>
         Patients are alerted to seek medical attention if they develop fever or difficulty voiding. A small amount of bright red blood per rectum is expected, but persistent rectal bleeding warrants immediate evaluation. Similar considerations apply to moderate hematuria, which should also be self-limited. Hematospermia is common after prostate biopsy, and discoloration of the semen may persist for weeks. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Patient follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Under most circumstances (providing the patient does not experience any complications), initial follow-up to discuss the pathology results will be over the phone. The results of the biopsy may be positive or negative for cancer or equivocal with respect to adequacy or histology. The interpretation of prostate biopsy histology is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6924.html" rel="external">
          "Interpretation of prostate biopsy", section on 'Histologic features'
         </a>
         .)
        </p>
        <p>
         Men with adequate and negative extended biopsies should resume follow-up with their primary care clinician or specialist physician, who may obtain "reflex" biomarker tests to estimate whether the biopsy has missed an aggressive cancer. Benign biopsy tissue may also be sent for DNA methylation abnormality testing (ConfirmMDx test) if available. (See
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer", section on 'Nonmetastatic disease'
         </a>
         .)
        </p>
        <p>
         By contrast, face-to-face consultation with an appropriate specialist is warranted in patients with positive or suspicious pathology. Patients with a diagnosis of prostate cancer will require additional staging prior to treatment. (See
         <a class="medical medical_review" href="/z/d/html/6939.html" rel="external">
          "Clinical presentation and diagnosis of prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6940.html" rel="external">
          "Initial approach to low- and very low-risk clinically localized prostate cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">
          "Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2891905557">
         <span class="h2">
          Repeat biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision about repeat prostate biopsy depends on many factors. If MRI is performed and a suspicious lesion (Prostate Imaging Reporting and Data System [PI-RADS] 3 or greater) is identified, then the MRI-targeted biopsy should follow. If MRI is not available or shows no suspicious lesion, further management depends on the clinical suspicion for prostate cancer (based on prostate-specific antigen [PSA] level, size of the prostate, etc): low-risk patients may be followed, intermediate-risk patients may undergo repeat TRUS biopsy, and high-risk patients may undergo saturation/template-guided biopsy. (See
         <a class="local">
          'Repeat systematic biopsy'
         </a>
         above and
         <a class="local">
          'Template-guided transperineal biopsy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3977233189">
         <span class="h3">
          Yield of repeat biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the acceptable diagnostic yield of prostate biopsy, it remains a sampling technique with a substantial potential for misdiagnosis.
        </p>
        <p>
         The potential yield of a repeat biopsy was illustrated by a series of 10,400 men undergoing prostate biopsy in the linked Surveillance, Epidemiology, and End Results (SEER) and Medicare database [
         <a href="#rid175">
          175
         </a>
         ]. The overall proportion of repeat biopsies found to contain prostate cancer was 32 percent and increased with age: 26 percent at 65 to 69 years, 31 percent at 70 to 74 years, 35 percent at 75 to 79 years, and 41 percent at ≥80 years. Among men whose first recorded biopsy did not detect prostate cancer, the need to have a subsequent biopsy was 12 percent at one year and 38 percent at five years.
        </p>
        <p>
         Similar findings were noted in other studies as prostate cancer was detected in up to 39 percent of patients at second biopsy [
         <a href="#rid176">
          176-180
         </a>
         ]. Further biopsies were not likely to be helpful, since the likelihood of detecting cancer was only to 10 to 17 percent on a third biopsy and 4 to 14 percent on a fourth biopsy [
         <a href="#rid176">
          176,178
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2147468147">
         <span class="h3">
          Indications for repeat biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for repeat biopsy are the finding of abnormal but nonmalignant pathology, rising PSA after a negative biopsy, and concerns for inadequate sampling.
        </p>
        <p class="headingAnchor" id="H2921326">
         <span class="h4">
          Abnormal histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of certain abnormal nonmalignant histology in the initial biopsy specimen may warrant further testing, which may include repeat systematic biopsy with consideration of MRI targeted biopsy, PSA, as well as urine or serum biomarkers [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-grade prostatic intraepithelial neoplasia
         </strong>
         – Prostatic intraepithelial neoplasia (PIN) is defined pathologically as abnormal cellular change within the prostatic ductal cells consistent with prostate cancer but without invasion of the basement membrane [
         <a href="#rid181">
          181
         </a>
         ]. PIN is divided into low-grade and high-grade subtypes. A majority of pathologists will not comment on findings of low-grade PIN, as evidence suggests that this histologic pattern is not premalignant [
         <a href="#rid182">
          182
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When discovered, high-grade PIN (HGPIN) is often multifocal (defined as HGPIN found on at least four biopsy cores) and typically located within the peripheral zone of the prostate [
         <a href="#rid183">
          183-185
         </a>
         ]. Multifocal HGPIN is associated with a 50 to 80 percent rate of cancer detection on repeat biopsy [
         <a href="#rid185">
          185-187
         </a>
         ]. Thus, patients with multifocal HGPIN should undergo early repeat biopsy, whereas patients with unifocal HGPIN may not require repeat biopsy unless PSA velocity is elevated or there are changes in the digital rectal examination. (See
         <a class="medical medical_review" href="/z/d/html/6925.html" rel="external">
          "Precancerous lesions of the prostate: Pathology and clinical implications", section on 'Management of high-grade PIN'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical small acinar proliferation
         </strong>
         – Atypical small acinar proliferation (ASAP) is defined as highly suspicious glandular architecture that is insufficient for the diagnosis of prostate cancer [
         <a href="#rid188">
          188
         </a>
         ]. An ASAP finding alone on prostate biopsy is associated with a 30 to 50 percent risk of prostate cancer detection on repeat biopsy, with approximately 10 to 20 percent of these being clinically significant [
         <a href="#rid189">
          189-194
         </a>
         ]. Although prostatic inflammation may be confused with ASAP, the independently predictive value of ASAP indicates that all patients with this diagnosis at the time of initial biopsy should undergo additional testing. (See
         <a class="medical medical_review" href="/z/d/html/6925.html" rel="external">
          "Precancerous lesions of the prostate: Pathology and clinical implications", section on 'Atypical small acinar proliferation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical intraductal proliferation
         </strong>
         – Atypical intraductal proliferation (AIP) describes lesions with greater architectural complexity and/or cytologic atypia than HGPIN but lacking definitive criteria for the diagnosis of intraductal carcinoma (IDC-P) [
         <a href="#rid195">
          195
         </a>
         ]. AIP encompasses many of the lesions formerly designated cribriform HGPIN, exhibiting loose cribriform architecture with moderate cytologic atypia, but lacking marked pleomorphism or necrosis [
         <a href="#rid196">
          196
         </a>
         ]. Given the association between AIP and undiagnosed IDC-P [
         <a href="#rid197">
          197-199
         </a>
         ], a finding of AIP as either alone or together with low-risk cancer warrants additional testing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2921333">
         <span class="h4">
          Rising PSA after biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeat biopsy may be considered in patients with a rising serum PSA after a negative initial biopsy [
         <a href="#rid200">
          200
         </a>
         ]. In these patients, PSA velocity, free-to-total PSA, and other urine or serum biomarkers have shown promise in guiding clinical decision-making regarding repeat prostate biopsy. (See
         <a class="medical medical_review" href="/z/d/html/7567.html" rel="external">
          "Screening for prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2921348">
         <span class="h4">
          Sampling considerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         When performing a repeat biopsy, an MRI-targeted biopsy with systematic biopsy or extended-core sampling technique should be used [
         <a href="#rid177">
          177,178,200-202
         </a>
         ]. The lateral peripheral zone should be thoroughly sampled preferentially over the anterior aspect or transition zone because the anterior regions have a lower yield [
         <a href="#rid179">
          179,180,203-205
         </a>
         ]. (See
         <a class="local">
          'Patients with negative systematic biopsy'
         </a>
         above.)
        </p>
        <p>
         When interpreting the pathology report, it should be determined whether an appropriate number of core samples were of adequate quality; a core sample is not adequate if prostatic glands or stroma are not visualized. Patients with a negative biopsy who have undergone inadequate (ie, low number of quality cores) or prior limited (ie, sextant) biopsy are at increased risk for a missed diagnosis of prostate cancer and should be considered for repeat biopsy.
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common complications of prostate biopsy include bleeding, infection, and urinary obstruction. There are more infectious complications after transrectal than transperineal biopsies, but the overall complication rates of the two approaches are similar. (See
         <a class="local">
          'Transperineal biopsy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Minor urinary or rectal bleeding is common and to be expected after prostate biopsy, which is generally self-limited, and &lt;1 percent require intervention [
         <a href="#rid206">
          206,207
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematuria
         </strong>
         – Visible hematuria following biopsy is common with reported rates ranging from 10 to 84 percent [
         <a href="#rid207">
          207
         </a>
         ]. In a retrospective review of 5802 transrectal ultrasound (TRUS)-guided sextant biopsies, hematuria and/or hematospermia occurred in approximately 50 percent of patients and lasted more than three days in 23 percent of patients [
         <a href="#rid208">
          208
         </a>
         ]. However, most hematuria that occurs after prostate biopsy is self-limited; only 0.4 percent require urethral catheterization and hospital admission for gross hematuria and/or clot retention [
         <a href="#rid163">
          163
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rectal bleeding
         </strong>
         – The risk of rectal bleeding varies between 1.3 and 58.6 percent and increases with an increasing number of sample cores and with anticoagulation [
         <a href="#rid70">
          70,207,209
         </a>
         ], but severe rectal bleeding requiring intervention occurs in fewer than 1 percent of procedures [
         <a href="#rid207">
          207,210
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the hemodynamically stable patient who is experiencing brisk rectal bleeding, manual digital compression of the prostate is the first-line strategy; rectal packing with gauze can also be used [
         <a href="#rid211">
          211
         </a>
         ]. Alternatively, a Foley catheter can be inserted into the rectum and inflated to 50 mL to tamponade the bleeding [
         <a href="#rid212">
          212
         </a>
         ]. As direct pressure is being applied, the patient's vital signs are monitored and coagulation parameters checked and corrected, as needed. In the event that bleeding continues or the patient becomes hemodynamically unstable, endoscopic (eg,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         injection, Endoclip) or surgical (ie, ligation) intervention may be required [
         <a href="#rid211">
          211,213
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematospermia
         </strong>
         – Hematospermia (hemoejaculate) occurs in 1.1 to 93 percent of men after prostate biopsy. Although a minor complication, it can persist for as long as four weeks in a third of the patients [
         <a href="#rid214">
          214
         </a>
         ]. Prebiopsy counseling is required to alleviate anxiety. (See
         <a class="medical medical_review" href="/z/d/html/6888.html" rel="external">
          "Hematospermia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          Infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infectious complications are the most common complications of prostate biopsy and the most common reason for hospitalization. They occur in 0.1 to 7 percent (sepsis 0.3 to 3.1 percent) of patients who undergo transrectal prostate biopsy [
         <a href="#rid215">
          215-217
         </a>
         ]. Between 1.1 and 1.9 percent of patients are hospitalized due to an infectious complication [
         <a href="#rid21">
          21,218
         </a>
         ]. The most common cause of infection after transrectal prostate biopsy is fluoroquinolone-resistant
         <em>
          E. coli
         </em>
         , the presence of which increases the risk of infection by four-fold [
         <a href="#rid219">
          219-221
         </a>
         ]. (See
         <a class="local">
          'Transrectal biopsy'
         </a>
         above.)
        </p>
        <p>
         Infectious complications include urinary tract infection, urosepsis, and prostatitis. Antibiotic prophylaxis before biopsy decreases the rate of infectious complications, but some patients are still at risk for serious infectious complications despite prophylaxis. (See
         <a class="local">
          'Prophylactic antibiotics'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urinary tract infection
         </strong>
         – Urinary tract infection is the most common infectious complication of prostate biopsy, occurring in 1 to 11 percent of patients [
         <a href="#rid14">
          14,30,207,222-224
         </a>
         ]. Treatment with oral antibiotics (eg, fluoroquinolone,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         ) is generally sufficient, though hospitalization and intravenous antibiotics may be required [
         <a href="#rid209">
          209,225
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">
          "Acute simple cystitis in adult and adolescent males", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urosepsis
         </strong>
         – In an observational study of 2023 patients who received antibiotics prior to prostate biopsy, 3 percent became septic [
         <a href="#rid226">
          226
         </a>
         ]. Predictive risk factors for sepsis included presence of an indwelling urethral catheter, diabetes mellitus, or biopsy with more than 10 cores. In other reviews, these factors and others, including hospitalization in the month prior to biopsy, chronic obstructive pulmonary disease, a history of recent antibiotic usage, or international travel, were identified as increasing the risk for infection [
         <a href="#rid227">
          227,228
         </a>
         ]. (See
         <a class="local">
          'Prophylactic antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who present with a fever after prostate biopsy should be assessed for sepsis. Patients who develop sepsis after transrectal prostate biopsy should be empirically treated with intravenous carbapenems,
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         , or a second- or third-generation cephalosporin until blood culture data are available. If bacteremia is suspected, oral fluoroquinolone or
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         is
         <strong>
          not
         </strong>
         an adequate choice given the high risk of resistance [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prostatitis
         </strong>
         – Acute postbiopsy prostatitis is a relatively uncommon but potentially life-threatening complication that warrants immediate evaluation and intervention. Prior fluoroquinolone use and extended postbiopsy antibiotic regimens appear to increase the risk for postbiopsy prostatitis [
         <a href="#rid216">
          216,229,230
         </a>
         ]. Treatment of acute prostatitis are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8062.html" rel="external">
          "Acute bacterial prostatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Urinary obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because patients may develop a degree of urinary obstruction due to acute postbiopsy prostatic inflammation, assessment of postvoid residual with a bladder scan should be performed for symptomatic patients. Alpha-blocker therapy can be initiated for patients with residual urine volumes of less than 100 mL, while insertion of a small-caliber (12 to 16 Fr) urethral catheter (or suprapubic catheter) is warranted in patients with higher residual volumes. Symptomatic patients should also be placed on stool softeners to ease mechanical strain on the prostate during bowel movements. (See
         <a class="medical medical_review" href="/z/d/html/6883.html" rel="external">
          "Acute urinary retention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8090.html" rel="external">
          "Placement and management of urinary bladder catheters in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1856463586">
         <span class="h2">
          Erectile dysfunction (rare)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erectile dysfunction is a rare, poorly understood complication of TRUS-guided prostate biopsy. The exact mechanism is unknown, but hypotheses about the cause include periprocedural anxiety, pain, apprehension about biopsy results, needle injury to the cavernosal nerves, cancer effects, and local tissue edema from the nerve block and hemorrhage [
         <a href="#rid17">
          17
         </a>
         ]. Patients should be counselled about possible, at least short-term, changes in erectile function after TRUS-guided biopsy.
        </p>
        <p class="headingAnchor" id="H1240755">
         <span class="h2">
          Tumor seeding (rare)
         </span>
         <span class="headingEndMark">
          —
         </span>
         A common patient concern is the possibility of spreading cancer cells within the prostate. Although isolated cases of tumor seeding the needle tract have been reported, these are rare and more often associated with the transperineal compared with a transrectal approach [
         <a href="#rid231">
          231,232
         </a>
         ]. The very low risk of tumor seeding should not preclude an indicated biopsy.
        </p>
        <p class="headingAnchor" id="H3138437049">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117831.html" rel="external">
          "Society guideline links: Diagnosis and management of prostate cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for prostate biopsy
         </strong>
         – Prostate biopsy is performed in patients with abnormal prostate-specific antigen (PSA) levels or abnormal digital rectal examination, or as a part of active surveillance. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of biopsy methods
         </strong>
         – Prostate biopsy can be systematic, targeted, or both, the choice of which depends on demonstration of suspicious findings on prebiopsy MRI. The requirement for prebiopsy MRI further depends on whether the patient has had a prior systematic biopsy  (
         <a class="graphic graphic_algorithm graphicRef142833" href="/z/d/graphic/142833.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Choice of biopsy method by indication'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial biopsy
         </strong>
         – Patients undergoing prostate biopsy for the first time may either have a systematic biopsy or an MRI first. If there are suspicious findings on MRI, a targeted biopsy should be performed with or without a concurrent systematic biopsy; if there are no suspicious findings on MRI, a systematic biopsy is performed. (See
         <a class="local">
          'Initial biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Repeat biopsy
         </strong>
         – For patients undergoing a repeat biopsy, we perform a prebiopsy MRI if one has not been done previously. If there are suspicious findings on MRI, a targeted biopsy should be performed with a concurrent systematic biopsy; if there are no suspicious findings on MRI, a systematic biopsy is performed; for repeat systematic biopsy, a more extensive sampling method such as saturation biopsy or template-guided biopsy may be considered. (See
         <a class="local">
          'Patients with negative systematic biopsy'
         </a>
         above and
         <a class="local">
          'Active surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of image guidance and anatomic approaches does not affect biopsy performance and are determined by operator preference.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systematic versus targeted biopsy
         </strong>
         – There is increasing evidence that MRI-targeted biopsy can increase clinically significant cancer detection over standard transrectal ultrasound (TRUS) biopsy alone, and this advantage is more pronounced when MRI-targeted biopsy is performed in men with a prior negative biopsy than biopsy-naïve men. (See
         <a class="local">
          'Systematic versus targeted biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         TRUS-guided prostate biopsy is the most common approach for patients undergoing prostate biopsy for the first time. For initial TRUS biopsy, we perform an extended 10- to 12-core biopsy rather than a sextant biopsy or a more extensive (eg, 18-core) biopsy. Apical and far-lateral regions of the prostate should be adequately sampled. (See
         <a class="local">
          'Systematic biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         At facilities where prostate MRI and MRI-targeted biopsy are available, MRI-targeted biopsy should be performed with concurrent systematic sampling for patients. (See
         <a class="local">
          'Targeted biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transrectal versus transperineal biopsy
         </strong>
         – Use of transperineal versus transrectal biopsy varies widely by country and within regions of specific countries. The reported cancer detection rates associated with transrectal versus transperineal biopsy route are not significantly different in contemporary studies. (See
         <a class="local">
          'Anatomic approaches'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotic prophylaxis
         </strong>
         – For patients undergoing prostate biopsy, we recommend antibiotic prophylaxis prior to transrectal prostate biopsy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). For patients without risk factors (eg, immunocompromised), antibiotic prophylaxis is not required before transperineal biopsy because of a lower risk of infection. (See
         <a class="local">
          'Prophylactic antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Need for repeat biopsy
         </strong>
         – Indications for repeat biopsy include abnormal but nonmalignant pathology (see below), rising PSA after a negative biopsy, and concerns for inadequate sampling (see
         <a class="local">
          'Repeat biopsy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with atypical small acinar proliferation (ASAP), atypical intraductal proliferation (AIP), or high-grade prostatic intraepithelial neoplasm (HGPIN) on initial biopsy should undergo further testing, including repeat biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Repeat biopsy may be considered in patients with a rising serum PSA after a negative initial biopsy after considering PSA velocity, free-to-total PSA, and other urine or serum biomarkers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Common complications of prostate biopsy include infection, bleeding, and urinary obstruction. There are fewer infectious complications after transperineal than transrectal biopsies, but the overall complication rates of the two approaches are similar. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2179064097">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Gerald L Andriole, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulgham PF, Rukstalis DB, Turkbey IB, et al. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol 2017; 198:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouvière O. Choosing the Right Diagnostic Pathway in Biopsy-Naive Patients With Suspected Prostate Cancer. JAMA Oncol 2021; 7:542.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN Guidelines. Treatment by Cancer Type. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on December 16, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol 2023; 210:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol 2016; 196:1613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drost FH, Osses DF, Nieboer D, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 2019; 4:CD012663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drost FH, Osses D, Nieboer D, et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. Eur Urol 2020; 77:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filson CP, Natarajan S, Margolis DJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer 2016; 122:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mannaerts CK, Kajtazovic A, Lodeizen OAP, et al. The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy. Urol Oncol 2019; 37:298.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elkhoury FF, Felker ER, Kwan L, et al. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surg 2019; 154:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol 2022; 208:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crawford ED, Haynes AL Jr, Story MW, Borden TA. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 1982; 127:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapoor DA, Klimberg IW, Malek GH, et al. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology 1998; 52:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindstedt S, Lindström U, Ljunggren E, et al. Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors. Eur Urol 2006; 50:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aus G, Ahlgren G, Bergdahl S, Hugosson J. Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis. Br J Urol 1996; 77:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liss MA, Ehdaie B, Loeb S, et al. An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. J Urol 2017; 198:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol 2020; 203:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011; :CD006576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puig J, Darnell A, Bermúdez P, et al. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary? Eur Radiol 2006; 16:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor AK, Zembower TR, Nadler RB, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012; 187:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liss MA, Chang A, Santos R, et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 2011; 185:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liss MA, Peterson EM, Johnston B, et al. Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology 2013; 81:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duplessis CA, Bavaro M, Simons MP, et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012; 79:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakil J, Piracha N, Prasad N, et al. Use of outpatient parenteral antimicrobial therapy for transrectal ultrasound-guided prostate biopsy prophylaxis in the setting of community-associated multidrug-resistant Escherichia coli rectal colonization. Urology 2014; 83:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tops SCM, Kolwijck E, Koldewijn EL, et al. Rectal Culture-Based Versus Empirical Antibiotic Prophylaxis to Prevent Infectious Complications in Men Undergoing Transrectal Prostate Biopsy: A Randomized, Nonblinded Multicenter Trial. Clin Infect Dis 2023; 76:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilatz A, Dimitropoulos K, Veeratterapillay R, et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol 2020; 204:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basourakos SP, Alshak MN, Lewicki PJ, et al. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci 2022; 37:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacewicz M, Günzel K, Rud E, et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2022; 22:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaytoun OM, Anil T, Moussa AS, et al. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 2011; 77:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis M, Sofer M, Kim SS, Soloway MS. The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J Urol 2002; 167:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abughosh Z, Margolick J, Goldenberg SL, et al. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol 2013; 189:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han KS, Lee KH, Korean Urologic Oncology Society Prostate Cancer Study Group. Factors influencing pain during transrectal ultrasonography-guided prostate biopsy. Prostate Cancer Prostatic Dis 2008; 11:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadway P, Barrett LK, Waghorn DJ, et al. Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy. BJU Int 2009; 104:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Issa MM, Al-Qassab UA, Hall J, et al. Formalin disinfection of biopsy needle minimizes the risk of sepsis following prostate biopsy. J Urol 2013; 190:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014; 192:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ihezue CU, Smart J, Dewbury KC, et al. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications. Clin Radiol 2005; 60:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannarini G, Mogorovich A, Valent F, et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 2007; 70:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maan Z, Cutting CW, Patel U, et al. Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. BJU Int 2003; 91:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghani KR, Rockall AG, Nargund VH, Chinegwundoh FI. Prostate biopsy: to stop anticoagulation or not? BJU Int 2006; 97:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mukerji G, Munasinghe I, Raza A. A survey of the peri-operative management of urological patients on clopidogrel. Ann R Coll Surg Engl 2009; 91:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galetti TP, Dal Moro F, Milani C, et al. Patient's preparation in order to reduce pain, anxiety, and complications of TRUS prostatic biopsies. Eur Urol 2002; 1:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingber MS, Ibrahim I, Turzewski C, et al. Does periprostatic block reduce pain during transrectal prostate biopsy? A randomized, placebo-controlled, double-blinded study. Int Urol Nephrol 2010; 42:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantiello F, Imperatore V, Iannuzzo M, et al. Periprostatic nerve block (PNB) alone vs PNB combined with an anaesthetic-myorelaxant agent cream for prostate biopsy: a prospective, randomized double-arm study. BJU Int 2009; 103:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yurdakul T, Taspinar B, Kilic O, et al. Topical and long-acting local anesthetic for prostate biopsy: a prospective randomized placebo-controlled study. Urol Int 2009; 83:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song SH, Kim JK, Song K, et al. Effectiveness of local anaesthesia techniques in patients undergoing transrectal ultrasound-guided prostate biopsy: a prospective randomized study. Int J Urol 2006; 13:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szlauer R, Gotschl R, Gnad A, et al. Comparison of lidocaine suppositories and periprostatic nerve block during transrectal prostate biopsy. Urol Int 2008; 80:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannarini G, Autorino R, Valent F, et al. Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial. J Urol 2009; 181:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irani J, Fournier F, Bon D, et al. Patient tolerance of transrectal ultrasound-guided biopsy of the prostate. Br J Urol 1997; 79:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matlaga BR, Lovato JF, Hall MC. Randomized prospective trial of a novel local anesthetic technique for extensive prostate biopsy. Urology 2003; 61:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turgut AT, Olçücüoğlu E, Koşar P, et al. Complications and limitations related to periprostatic local anesthesia before TRUS-guided prostate biopsy. J Clin Ultrasound 2008; 36:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubo Y, Kawakami S, Numao N, et al. Simple and effective local anesthesia for transperineal extended prostate biopsy: application to three-dimensional 26-core biopsy. Int J Urol 2009; 16:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tüfek I, Akpinar H, Atuğ F, et al. The impact of local anesthetic volume and concentration on pain during prostate biopsy: a prospective randomized trial. J Endourol 2012; 26:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bingqian L, Peihuan L, Yudong W, et al. Intraprostatic local anesthesia with periprostatic nerve block for transrectal ultrasound guided prostate biopsy. J Urol 2009; 182:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashley RA, Inman BA, Routh JC, et al. Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. Cancer 2007; 110:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuppusamy S, Faizal N, Quek KF, et al. The efficacy of periprostatic local anaesthetic infiltration in transrectal ultrasound biopsy of prostate: a prospective randomised control study. World J Urol 2010; 28:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Wang L, Du Y, et al. Addition of intrarectal local analgesia to periprostatic nerve block improves pain control for transrectal ultrasonography-guided prostate biopsy: a systematic review and meta-analysis. Int J Urol 2015; 22:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skriapas K, Konstantinidis C, Samarinas M, et al. Comparison between lidocaine and glyceryl trinitrate ointment for perianal-intrarectal local anesthesia before transrectal ultrasonography-guided prostate biopsy: a placebo-controlled trial. Urology 2011; 77:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantiello F, Cicione A, Autorino R, et al. Pelvic plexus block is more effective than periprostatic nerve block for pain control during office transrectal ultrasound guided prostate biopsy: a single center, prospective, randomized, double arm study. J Urol 2012; 188:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obi AO, Okafor VU, Nnodi PI. Prospective randomized trial of spinal saddle block versus periprostatic lignocaine for anesthesia during transrectal prostate biopsy. Urology 2011; 77:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gosselaar C, Roobol MJ, Roemeling S, et al. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU Int 2008; 101:685.
          </a>
         </li>
         <li class="breakAll">
          American Urological Association. Optimal Techniques of Prostate Biopsy and Specimen Handling. Available at: https://www.auanet.org/guidelines/prostate-biopsy-and-specimen-handling (Accessed on April 29, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskicorapci SY, Guliyev F, Akdogan B, et al. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005; 173:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ukimura O, Coleman JA, de la Taille A, et al. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol 2013; 63:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskicorapci SY, Baydar DE, Akbal C, et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uno H, Nakano M, Ehara H, Deguchi T. Indications for extended 14-core transrectal ultrasound-guided prostate biopsy. Urology 2008; 71:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babaian RJ, Toi A, Kamoi K, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000; 163:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichler K, Hempel S, Wilby J, et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghani KR, Dundas D, Patel U. Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol. BJU Int 2004; 94:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scattoni V, Roscigno M, Raber M, et al. Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores? J Urol 2008; 179:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ankerst DP, Till C, Boeck A, et al. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. J Urol 2013; 190:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remzi M, Fong YK, Dobrovits M, et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sajadi KP, Kim T, Terris MK, et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 2007; 70:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaytoun OM, Moussa AS, Gao T, et al. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol 2011; 186:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li YH, Elshafei A, Li J, et al. Potential benefit of transrectal saturation prostate biopsy as an initial biopsy strategy: decreased likelihood of finding significant cancer on future biopsy. Urology 2014; 83:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irani J, Blanchet P, Salomon L, et al. Is an extended 20-core prostate biopsy protocol more efficient than the standard 12-core? A randomized multicenter trial. J Urol 2013; 190:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007; 70:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang X, Zhu S, Feng G, et al. Is an initial saturation prostate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta-analysis. Eur Urol 2013; 63:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böcking A. [Cytopathology of the prostate]. Pathologe 1998; 19:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012; 30:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vourganti S, Rastinehad A, Yerram NK, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012; 188:2152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012; 62:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico AV, Tempany CM, Cormack R, et al. Transperineal magnetic resonance image guided prostate biopsy. J Urol 2000; 164:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yakar D, Hambrock T, Hoeks C, et al. Magnetic resonance-guided biopsy of the prostate: feasibility, technique, and clinical applications. Top Magn Reson Imaging 2008; 19:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adusumilli S, Pretorius ES. Magnetic resonance imaging of prostate cancer. Semin Urol Oncol 2002; 20:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenfeld P, Hata N, DiMaio S, et al. Transperineal prostate biopsy under magnetic resonance image guidance: a needle placement accuracy study. J Magn Reson Imaging 2007; 26:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013; 63:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wysock JS, Rosenkrantz AB, Huang WC, et al. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 2014; 66:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyagawa T, Ishikawa S, Kimura T, et al. Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol 2010; 17:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadaschik BA, Kuru TH, Tulea C, et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol 2011; 186:2214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012; 62:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 2013; 64:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brisbane WG, Priester AM, Ballon J, et al. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. Eur Urol 2022; 82:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017; 389:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018; 378:1767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porpiglia F, Manfredi M, Mele F, et al. Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer. Eur Urol 2017; 72:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klotz L, Chin J, Black PC, et al. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med 2020; 382:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newton MR, Phillips S, Chang SS, et al. Smaller prostate size predicts high grade prostate cancer at final pathology. J Urol 2010; 184:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 1995; 195:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinohara K, Scardino PT, Carter SS, Wheeler TM. Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am 1989; 16:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinohara K, Wheeler TM, Scardino PT. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol 1989; 142:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27:4321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience. Urology 2007; 70:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitterberger M, Pinggera GM, Pallwein L, et al. The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int 2007; 100:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derigs F, Kowalewski KF, Hartung FO, et al. A Matched-pair Analysis Comparing Systematic Prostate Biopsy by Conventional Transrectal Ultrasound-guidance Versus Software-based Predefined 3D-Guidance. Urology 2023; 177:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thoma C. Prostate cancer: MRI/TRUS fusion outperforms standard and combined biopsy approaches. Nat Rev Urol 2015; 12:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results, and potential applications of color Doppler US scanning. Radiology 1993; 186:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halpern EJ, Strup SE. Using gray-scale and color and power Doppler sonography to detect prostatic cancer. AJR Am J Roentgenol 2000; 174:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson ED, Slotoroff CB, Gomella LG, Halpern EJ. Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score. Urology 2007; 70:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halpern EJ, Frauscher F, Strup SE, et al. Prostate: high-frequency Doppler US imaging for cancer detection. Radiology 2002; 225:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aigner F, Mitterberger M, Rehder P, et al. Status of transrectal ultrasound imaging of the prostate. J Endourol 2010; 24:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trabulsi EJ, Sackett D, Gomella LG, Halpern EJ. Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer. Urology 2010; 76:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smeenge M, Mischi M, Laguna Pes MP, et al. Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol 2011; 29:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aigner F, Schäfer G, Steiner E, et al. Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: a retrospective data analysis. World J Urol 2012; 30:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kundavaram CR, Halpern EJ, Trabulsi EJ. Value of contrast-enhanced ultrasonography in prostate cancer. Curr Opin Urol 2012; 22:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smeenge M, de la Rosette JJ, Wijkstra H. Current status of transrectal ultrasound techniques in prostate cancer. Curr Opin Urol 2012; 22:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie SW, Li HL, Du J, et al. Contrast-enhanced ultrasonography with contrast-tuned imaging technology for the detection of prostate cancer: comparison with conventional ultrasonography. BJU Int 2012; 109:1620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao HX, Zhu Q, Wang ZC. Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy results. Br J Radiol 2012; 85:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aboumarzouk OM, Ogston S, Huang Z, et al. Diagnostic accuracy of transrectal elastosonography (TRES) imaging for the diagnosis of prostate cancer: a systematic review and meta-analysis. BJU Int 2012; 110:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapoor A, Kapoor A, Mahajan G, Sidhu BS. Real-time elastography in the detection of prostate cancer in patients with raised PSA level. Ultrasound Med Biol 2011; 37:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganzer R, Brandtner A, Wieland WF, Fritsche HM. Prospective blinded comparison of real-time sonoelastography targeted versus randomised biopsy of the prostate in the primary and re-biopsy setting. World J Urol 2012; 30:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brock M, von Bodman C, Palisaar RJ, et al. The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients. J Urol 2012; 187:2039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Tang J, Li YM, et al. Differentiation of prostate cancer from benign lesions using strain index of transrectal real-time tissue elastography. Eur J Radiol 2012; 81:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krouskop TA, Wheeler TM, Kallel F, et al. Elastic moduli of breast and prostate tissues under compression. Ultrason Imaging 1998; 20:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumura M, Shigeno K, Hyuga T, et al. Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study. Int J Urol 2007; 14:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pallwein L, Mitterberger M, Struve P, et al. Real-time elastography for detecting prostate cancer: preliminary experience. BJU Int 2007; 100:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salomon G, Köllerman J, Thederan I, et al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol 2008; 54:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claros OR, Tourinho-Barbosa RR, Fregeville A, et al. Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer. J Urol 2020; 203:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiemer L, Hollenbach M, Heckmann R, et al. Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway. Eur Urol Focus 2021; 7:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lughezzani G, Maffei D, Saita A, et al. Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective Study. Eur Urol Focus 2021; 7:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sountoulides P, Pyrgidis N, Polyzos SA, et al. Micro-Ultrasound-Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. J Urol 2021; 205:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lughezzani G, Saita A, Lazzeri M, et al. Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol 2019; 2:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klotz L, Andriole G, Cash H, et al. Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemp Clin Trials 2022; 112:106618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward AD, Crukley C, McKenzie CA, et al. Prostate: registration of digital histopathologic images to in vivo MR images acquired by using endorectal receive coil. Radiology 2012; 263:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015; 313:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padhani AR, Weinreb J, Rosenkrantz AB, et al. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. Eur Urol 2019; 75:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israël B, Leest MV, Sedelaar M, et al. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. Eur Urol 2020; 77:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engels RRM, Israël B, Padhani AR, Barentsz JO. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition. Eur Urol 2020; 77:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venderink W, Bomers JG, Overduin CG, et al. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy. Eur Urol 2020; 77:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan-Marans E, Zhang TR, Hu JC. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol 2023; 84:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ristau BT, Allaway M, Cendo D, et al. Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template. Urol Oncol 2018; 36:528.e15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott S, Samaratunga H, Chabert C, et al. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis. BJU Int 2015; 116 Suppl 3:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiang J, Yan H, Li J, et al. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol 2019; 17:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buller D, Sahl J, Staff I, et al. Prostate Cancer Detection and Complications of Transperineal Versus Transrectal Magnetic Resonance Imaging-fusion Guided Prostate Biopsies. Urology 2023; 177:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boczko J, Messing E, Dogra V. Transrectal sonography in prostate evaluation. Radiol Clin North Am 2006; 44:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Öbek C, Doğanca T, Erdal S, et al. Core length in prostate biopsy: size matters. J Urol 2012; 187:2051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawakami S, Yamamoto S, Numao N, et al. Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer. Int J Urol 2007; 14:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moussa AS. Editorial comment. Urology 2011; 77:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hossack T, Patel MI, Huo A, et al. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. J Urol 2012; 188:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loy LM, Lim GH, Leow JJ, et al. A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection-Comparing transrectal with transperineal approaches. Urol Oncol 2020; 38:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grummet JP, Weerakoon M, Huang S, et al. Sepsis and 'superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int 2014; 114:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grummet J. How to Biopsy: Transperineal Versus Transrectal, Saturation Versus Targeted, What's the Evidence? Urol Clin North Am 2017; 44:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen PF, Zhu YC, Wei WR, et al. The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis. Asian J Androl 2012; 14:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepe P, Aragona F. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology 2013; 81:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Losa A, Gadda GM, Lazzeri M, et al. Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. Urology 2013; 81:1291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinkhasov GI, Lin YK, Palmerola R, et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int 2012; 110:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xue J, Qin Z, Cai H, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget 2017; 8:23322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gross MD, Shoag JE, Hu JC. Is in-office transperineal biopsy the future of prostate cancer diagnosis? Curr Opin Urol 2019; 29:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanova V, Buckley R, Flax S, et al. Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability. J Urol 2019; 201:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran BJ, Braccioforte MH. Stereotactic transperineal prostate biopsy. Urology 2009; 73:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symons JL, Huo A, Yuen CL, et al. Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int 2013; 112:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuru TH, Wadhwa K, Chang RT, et al. Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics. BJU Int 2013; 112:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michael ZD, Kotamarti S, Deivasigamani S, et al. A Comprehensive Assessment of the Utility of Transperineal Template Prostate Mapping Biopsy: A 13-year Experience. Urology 2023; 177:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer AR, Joice GA, Schwen ZR, et al. Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. Urology 2018; 115:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kum F, Elhage O, Maliyil J, et al. Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting. BJU Int 2020; 125:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CC, Huang WJ, Wu LJ, et al. Diagnosis of prostate cancer: repeated transrectal prostate biopsy or transurethral resection. J Chin Med Assoc 2008; 71:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coplen DE, Andriole GL, Yuan JJ, Catalona WJ. The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia. J Urol 1991; 146:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007; 99:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djavan B, Ravery V, Zlotta A, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001; 166:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskicorapci SY, Guliyev F, Islamoglu E, et al. The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique. Int Urol Nephrol 2007; 39:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos-Fernandes JL, Bastien L, Nicolaiew N, et al. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009; 55:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chon CH, Lai FC, McNeal JE, Presti JC Jr. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 2002; 167:2457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong YM, Lai FC, Chon CH, et al. Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies. Urol Oncol 2004; 22:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bostwick DG, Montironi R. Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Pathol Res Pract 1995; 191:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egevad L, Allsbrook WC Jr, Epstein JI. Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Hum Pathol 2006; 37:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Häggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997; 158:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishara T, Ramnani DM, Epstein JI. High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern. Am J Surg Pathol 2004; 28:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Nunzio C, Trucchi A, Miano R, et al. The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol 2009; 181:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoenfield L, Jones JS, Zippe CD, et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU Int 2007; 99:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein MH, Epstein JI. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993; 24:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abouassaly R, Tan N, Moussa A, Jones JS. Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol 2008; 180:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim TS, Ko KJ, Shin SJ, et al. Multiple cores of high grade prostatic intraepithelial neoplasia and any core of atypia on first biopsy are significant predictor for cancer detection at a repeat biopsy. Korean J Urol 2015; 56:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiener S, Haddock P, Cusano J, et al. Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue. Urology 2017; 110:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oderda M, Rosazza M, Agnello M, et al. Natural history of widespread high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: should we rebiopsy them all? Scand J Urol 2021; 55:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leone A, Gershman B, Rotker K, et al. Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review. Prostate Cancer Prostatic Dis 2016; 19:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warlick C, Feia K, Tomasini J, et al. Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation. Prostate Cancer Prostatic Dis 2015; 18:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorin RP, Wiener S, Harris CD, Wagner JR. Prostate atypia: does repeat biopsy detect clinically significant prostate cancer? Prostate 2015; 75:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah RB, Magi-Galluzzi C, Han B, Zhou M. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am J Surg Pathol 2010; 34:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah RB, Zhou M. Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate. Adv Anat Pathol 2012; 19:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah RB, Yoon J, Liu G, Tian W. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma. Histopathology 2017; 71:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hickman RA, Yu H, Li J, et al. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate. Am J Surg Pathol 2017; 41:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah RB, Nguyen JK, Przybycin CG, et al. Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. Histopathology 2019; 75:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djavan B, Remzi M, Schulman CC, et al. Repeat prostate biopsy: who, how and when?. a review. Eur Urol 2002; 42:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbani F, Stroumbakis N, Kava BR, et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997; 158:505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shariat SF, Roehrborn CG. Using biopsy to detect prostate cancer. Rev Urol 2008; 10:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Presti JC Jr. Repeat prostate biopsy--when, where, and how. Urol Oncol 2009; 27:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abd TT, Goodman M, Hall J, et al. Comparison of 12-core versus 8-core prostate biopsy: multivariate analysis of large series of US veterans. Urology 2011; 77:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halliwell OT, Yadegafar G, Lane C, Dewbury KC. Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications. Clin Radiol 2008; 63:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013; 64:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raaijmakers R, Kirkels WJ, Roobol MJ, et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djavan B, Waldert M, Zlotta A, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001; 166:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiang IN, Chang SJ, Pu YS, et al. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in taiwan. J Formos Med Assoc 2007; 106:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun KP, May M, Helke C, et al. Endoscopic therapy of a massive rectal bleeding after prostate biopsy. Int Urol Nephrol 2007; 39:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilciler M, Erdemir F, Demir E, et al. The effect of rectal Foley catheterization on rectal bleeding rates after transrectal ultrasound-guided prostate biopsy. J Vasc Interv Radiol 2008; 19:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsinelos P, Kountouras J, Dimitriadis G, et al. Endoclipping treatment of life-threatening rectal bleeding after prostate biopsy. World J Gastroenterol 2009; 15:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manoharan M, Ayyathurai R, Nieder AM, Soloway MS. Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study. Prostate Cancer Prostatic Dis 2007; 10:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011; 78:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumford D 3rd, Suwantarat N, Bhasker V, et al. Outbreak of fluoroquinolone-resistant Escherichia coli infections after transrectal ultrasound-guided biopsy of the prostate. Infect Control Hosp Epidemiol 2013; 34:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liss MA, Johnson JR, Porter SB, et al. Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis 2015; 60:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liss MA, Taylor SA, Batura D, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol 2014; 192:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts MJ, Williamson DA, Hadway P, et al. Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis. Int J Antimicrob Agents 2014; 43:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagenlehner FM, van Oostrum E, Tenke P, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013; 63:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanjanawongdeengam P, Viseshsindh W, Santanirand P, et al. Reduction in bacteremia rates after rectum sterilization before transrectal, ultrasound-guided prostate biopsy: a randomized controlled trial. J Med Assoc Thai 2009; 92:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campeggi A, Ouzaid I, Xylinas E, et al. Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol 2014; 21:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindert KA, Kabalin JN, Terris MK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J Urol 2000; 164:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simsir A, Kismali E, Mammadov R, et al. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int 2010; 84:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel U, Dasgupta P, Amoroso P, et al. Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int 2012; 109:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carignan A, Roussy JF, Lapointe V, et al. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol 2012; 62:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaytoun OM, Vargo EH, Rajan R, et al. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011; 77:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozden E, Bostanci Y, Yakupoglu KY, et al. Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy. Urology 2009; 74:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaghefi H, Magi-Galluzzi C, Klein EA. Local recurrence of prostate cancer in rectal submucosa after transrectal needle biopsy and radical prostatectomy. Urology 2005; 66:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moul JW, Bauer JJ, Srivastava S, et al. Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. Urology 1998; 51:158.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8097 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36912538" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28483574" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538770" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Choosing the Right Diagnostic Pathway in Biopsy-Naive Patients With Suspected Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538770" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Choosing the Right Diagnostic Pathway in Biopsy-Naive Patients With Suspected Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37096575" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27320841" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31022301" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31326219" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26749141" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660493" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31188412" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35536148" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6895918" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9763070" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16750292" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8705220" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28363690" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31441676" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21563156" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Antibiotic prophylaxis for transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16391904" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22341272" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21334021" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23333000" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22386395" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24680441" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of outpatient parenteral antimicrobial therapy for transrectal ultrasound-guided prostate biopsy prophylaxis in the setting of community-associated multidrug-resistant Escherichia coli rectal colonization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36419331" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Rectal Culture-Based Versus Empirical Antibiotic Prophylaxis to Prevent Infectious Complications in Men Undergoing Transrectal Prostate Biopsy: A Randomized, Nonblinded Multicenter Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32105195" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35243391" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35839791" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21316093" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11792920" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23041343" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17710107" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Factors influencing pain during transrectal ultrasonography-guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20053186" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23714433" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Formalin disinfection of biopsy needle minimizes the risk of sepsis following prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859439" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767103" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17688919" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12780835" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16430617" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prostate biopsy: to stop anticoagulation or not?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19344548" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A survey of the peri-operative management of urological patients on clopidogrel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Patient's preparation in order to reduce pain, anxiety, and complications of TRUS prostatic biopsies
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19669586" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Does periprostatic block reduce pain during transrectal prostate biopsy? A randomized, placebo-controlled, double-blinded study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19021624" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Periprostatic nerve block (PNB) alone vs PNB combined with an anaesthetic-myorelaxant agent cream for prostate biopsy: a prospective, randomized double-arm study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19752608" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Topical and long-acting local anesthetic for prostate biopsy: a prospective randomized placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16834647" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effectiveness of local anaesthesia techniques in patients undergoing transrectal ultrasound-guided prostate biopsy: a prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18480626" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparison of lidocaine suppositories and periprostatic nerve block during transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19084860" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block for pain control during transrectal ultrasound guided prostate biopsy: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9126093" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Patient tolerance of transrectal ultrasound-guided biopsy of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12736018" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Randomized prospective trial of a novel local anesthetic technique for extensive prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18058930" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Complications and limitations related to periprostatic local anesthesia before TRUS-guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19416405" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Simple and effective local anesthesia for transperineal extended prostate biopsy: application to three-dimensional 26-core biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22092389" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The impact of local anesthetic volume and concentration on pain during prostate biopsy: a prospective randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19524987" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Intraprostatic local anesthesia with periprostatic nerve block for transrectal ultrasound guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17724727" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20623289" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The efficacy of periprostatic local anaesthetic infiltration in transrectal ultrasound biopsy of prostate: a prospective randomised control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25141759" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Addition of intrarectal local analgesia to periprostatic nerve block improves pain control for transrectal ultrasonography-guided prostate biopsy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21316086" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Comparison between lidocaine and glyceryl trinitrate ointment for perianal-intrarectal local anesthesia before transrectal ultrasonography-guided prostate biopsy: a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22704121" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pelvic plexus block is more effective than periprostatic nerve block for pain control during office transrectal ultrasound guided prostate biopsy: a single center, prospective, randomized, double arm study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20970825" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Prospective randomized trial of spinal saddle block versus periprostatic lignocaine for anesthesia during transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18291017" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18291017" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15821481" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021971" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15041107" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18242358" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Indications for extended 14-core transrectal ultrasound-guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10604335" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2659827" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16600713" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15541119" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and 12-core biopsy protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18289580" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23313212" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16145388" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17991539" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21788047" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24680442" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Potential benefit of transrectal saturation prostate biopsy as an initial biopsy strategy: decreased likelihood of finding significant cancer on future biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23313205" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Is an extended 20-core prostate biopsy protocol more efficient than the standard 12-core? A randomized multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11435830" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18158033" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23414775" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Is an initial saturation prostate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9541942" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : [Cytopathology of the prostate].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21512807" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233291" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23083875" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22325447" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10893595" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10893591" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Transperineal magnetic resonance image guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19512851" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Magnetic resonance-guided biopsy of the prostate: feasibility, technique, and clinical applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12215973" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Magnetic resonance imaging of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17729363" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Transperineal prostate biopsy under magnetic resonance image guidance: a needle placement accuracy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21849184" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21931141" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Prostate cancer: multiparametric MR imaging for detection, localization, and staging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22743165" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262102" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20807266" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Real-time Virtual Sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22014798" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22819387" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23787357" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35115177" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28110982" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29552975" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27574821" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33538782" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32130814" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20643423" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Smaller prostate size predicts high grade prostate cancer at final pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7534429" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2683298" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Pathologic basis of the sonographic appearance of the normal and malignant prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2659828" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652073" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18194708" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17433033" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : The value of three-dimensional transrectal ultrasonography in staging prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37019390" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : A Matched-pair Analysis Comparing Systematic Prostate Biopsy by Conventional Transrectal Ultrasound-guidance Versus Software-based Predefined 3D-Guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25687268" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Prostate cancer: MRI/TRUS fusion outperforms standard and combined biopsy approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678467" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Prostate: techniques, results, and potential applications of color Doppler US scanning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10701599" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Using gray-scale and color and power Doppler sonography to detect prostatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18158034" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12354987" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Prostate: high-frequency Doppler US imaging for cancer detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20433367" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Status of transrectal ultrasound imaging of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20719368" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21847656" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Novel contrast-enhanced ultrasound imaging in prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22179312" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: a retrospective data analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22617061" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Value of contrast-enhanced ultrasonography in prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595778" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Current status of transrectal ultrasound techniques in prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21939490" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Contrast-enhanced ultrasonography with contrast-tuned imaging technology for the detection of prostate cancer: comparison with conventional ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21712427" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22616818" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Diagnostic accuracy of transrectal elastosonography (TRES) imaging for the diagnosis of prostate cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21816287" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Real-time elastography in the detection of prostate cancer in patients with raised PSA level.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21519851" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Prospective blinded comparison of real-time sonoelastography targeted versus randomised biopsy of the prostate in the primary and re-biopsy setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22498211" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21392908" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Differentiation of prostate cancer from benign lesions using strain index of transrectal real-time tissue elastography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197347" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Elastic moduli of breast and prostate tissues under compression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17760747" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17552952" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Real-time elastography for detecting prostate cancer: preliminary experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18374470" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31821099" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32654967" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33069624" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33577367" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Micro-Ultrasound-Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31200848" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34728381" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22474671" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Prostate: registration of digital histopathologic images to in vivo MR images acquired by using endorectal receive coil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25626035" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29908876" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31767492" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31582290" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31791623" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37296040" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30446447" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Free-hand transperineal prostate biopsy provides acceptable cancer detection and minimizes risk of infection: evolving experience with a 10-sector template.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26260531" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30760274" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37059232" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Prostate Cancer Detection and Complications of Transperineal Versus Transrectal Magnetic Resonance Imaging-fusion Guided Prostate Biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17030220" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Transrectal sonography in prostate evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22498214" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Core length in prostate biopsy: size matters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17681062" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Direct comparison between transrectal and transperineal extended prostate biopsy for the detection of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21477721" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Editorial comment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22819419" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32505458" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : A systematic review and meta-analysis of magnetic resonance imaging and ultrasound guided fusion biopsy of prostate for cancer detection-Comparing transrectal with transperineal approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24612341" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Sepsis and 'superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29107269" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : How to Biopsy: Transperineal Versus Transrectal, Saturation Versus Targeted, What's the Evidence?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22101942" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : The results of transperineal versus transrectal prostate biopsy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23726443" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23522299" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22313996" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28177897" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30407219" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Is in-office transperineal biopsy the future of prostate cancer diagnosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30835607" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19027936" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Stereotactic transperineal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23551500" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Outcomes of transperineal template-guided prostate biopsy in 409 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23773772" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37105359" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : A Comprehensive Assessment of the Utility of Transperineal Template Prostate Mapping Biopsy: A 13-year Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29409845" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30431694" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18818137" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Diagnosis of prostate cancer: repeated transrectal prostate biopsy or transurethral resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1711588" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17848671" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11586201" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16835725" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18597923" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11992057" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Use of extended systematic sampling in patients with a prior negative prostate needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14969796" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8606858" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16613324" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9186314" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15105651" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19150546" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17233800" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7684999" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635220" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26682019" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Multiple cores of high grade prostatic intraepithelial neoplasia and any core of atypia on first biopsy are significant predictor for cancer detection at a repeat biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28888752" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33410348" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Natural history of widespread high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: should we rebiopsy them all?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26857145" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25896264" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25597982" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Prostate atypia: does repeat biopsy detect clinically significant prostate cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20182345" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22692290" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28570007" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28009609" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31012493" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12160578" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Repeat prostate biopsy: who, how and when?. a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9507846" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Incidence and clinical significance of false-negative sextant prostate biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9224334" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19145270" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Using biopsy to detect prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19414120" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Repeat prostate biopsy--when, where, and how.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20817273" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Comparison of 12-core versus 8-core prostate biopsy: multivariate analysis of large series of US veterans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18374720" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Transrectal ultrasound-guided biopsy of the prostate: aspirin increases the incidence of minor bleeding complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23787356" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Systematic review of complications of prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12429309" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11490233" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18063514" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17333514" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Endoscopic therapy of a massive rectal bleeding after prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18725097" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : The effect of rectal Foley catheterization on rectal bleeding rates after transrectal ultrasound-guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19266608" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : Endoclipping treatment of life-threatening rectal bleeding after prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17310259" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21944136" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Complications after prostate biopsy: data from SEER-Medicare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21782225" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23388361" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : Outbreak of fluoroquinolone-resistant Escherichia coli infections after transrectal ultrasound-guided biopsy of the prostate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20089283" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25516194" id="rid218" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          219 : Clinical and microbiological determinants of infection after transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24928266" id="rid219" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          220 : Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24630305" id="rid220" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          221 : Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22704727" id="rid221" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          222 : Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20043564" id="rid222" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          223 : Reduction in bacteremia rates after rectum sterilization before transrectal, ultrasound-guided prostate biopsy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23906113" id="rid223" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          224 : Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10840428" id="rid224" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          225 : Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20224265" id="rid225" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          226 : Is it possible to predict sepsis, the most serious complication in prostate biopsy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22040349" id="rid226" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          227 : Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22575912" id="rid227" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          228 : Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21420152" id="rid228" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          229 : Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19464043" id="rid229" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          230 : Incidence of acute prostatitis caused by extended-spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16230172" id="rid230" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          231 : Local recurrence of prostate cancer in rectal submucosa after transrectal needle biopsy and radical prostatectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9457312" id="rid231" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          232 : Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
